In a press release on April 25, 2024, Quantum Genomics announces that it has obtained the approval of the General Meeting of Shareholders on the reduction of its share capital and on the contribution in kind of 100% of the shares of ExactCure.
The company Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC) announces that, as part of its merger project with the Nice-based healthtech Exactcure, which is developing an artificial intelligence software to adapt drug intake to the profile of each individual, the operations concerning the reduction of its share capital and the contribution of 100% of the shares of ExactCure were approved by the Shareholders at the Annual General Meeting held on April 24, 2024.
Quantum Genomics press release
The Mixed General Meeting of Quantum Genomics shareholders, held on April 24, 2024, validated, with a majority of at least 99.88% for each of the resolutions adopted, the company’s crucial strategic decisions.
The shareholders unanimously approved the capital reduction operation by dividing the par value, as well as the key operation of the contribution in kind of 277,031 shares of the company Exactcure, representing 100% of the capital and voting rights of the latter.
The meeting reached a quorum of 25.63%, allowing the Annual General Meeting to be held validly.
All the resolutions presented were ratified, demonstrating the full support of Quantum Genomics shareholders for the company’s ongoing projects.
First, the share capital of Quantum Genomics was reduced by 12,542,122.18 euros, bringing the nominal value of a share to approximately 0.04 euros. Then, following the contribution in kind, the company now holds 100% of the capital and voting rights of Exactcure, valued at 6 million euros, equivalent to the issuance of 34,854,973 new ordinary shares, each at a unit price of approximately 0.172142 euros.
These transactions led to an increase in the share capital of Quantum Genomics by 1,393,568.81 euros, bringing the total capital to 2,787,137.94 €, divided into 69,709,954 shares, each with a nominal value of approximately 0.04 euros.
Quantum Genomics is now the sole holder of all the shares and voting rights of Exactcure, thus consolidating its position in the market.
ExactCure, a Nice-based Healthtech gem
ExactCure stands out for its cutting-edge innovation in the Healthtech sector. The company was recognized in early 2023 by becoming a laureate of the i-Nov Innovation Competition for its INTERACTWIN project. It was also selected among the laureates of the 4th edition of the Pfizer Healthcare Hub France in early 2024. This recognition by giants of the pharmaceutical industry and entrepreneurial support attests to the potential impact and innovation brought by ExactCure in the field of digital health.
ExactCure’s main innovation lies in the development of its “Digital Twin.” This solution based on artificial intelligence enables healthcare professionals to simulate the concentration of drugs in a patient’s blood, taking into account their physical characteristics and metabolism. This technology aims to optimize drug dosage and prevent drug interactions, particularly for patients on multiple medications or those with altered metabolism. This development meets a crucial need in the field of personalized medicine and represents a significant advance in the management of drug treatments.
For further information concerning these operations, please refer to the initial press release published by Quantum Genomics on March 13, 2024.
Health Nice Côte d’Azur
- Eurobiomed H1 2026 review: nearly €250 M mobilised by the HealthTech industry in Southern France
- ExAdEx-Innov secures a U.S. patent on its technology for human ex vivo tissue models
- Nice University Hospital launches Health Data Warehouse to advance medical research and innovation
- 6th Life Sciences Afterwork organised by Team Nice Côte d’Azur
- Follow Health (Nice) joins European software group Orisha
- The Nice University Hospital performs its 100th liver transplantation since 2024
- Obesity: French first at Nice University Hospital
- Team Nice Côte d’Azur at the Van Lanschot Kempen Life Sciences Conference 2026
- Launch of the AZUR Territorial Research Entity to advance clinical research on the French Riviera
- BIO-Europe Spring 2026 : meet with Team Nice Côte d’Azur
